Market Size and Growth
Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach US$ 5.53 billion in 2025 and projected to reach US$ 10.49 billion by 2033, growing at a CAGR of 4.0% during the forecast period (2026-2033).
GERD is a digestive disorder that occurs when stomach contents such as acid, food, and fluids reflux into the esophagus. It irritates the esophageal lining, resulting in patients experiencing a burning sensation. Heartburn (reflux) and regurgitation are two of GERD's most common esophageal symptoms. In most cases, GERD symptoms can ease through diet and lifestyle changes. But some people may need medication or surgery.
Market Scope
| Metrics | Details |
| Market CAGR | 4.0% |
| Segments Covered | By Type, By Drug Class, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights: Request Free Sample
Market Dynamics
The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.
TIF (transoral incisionless fundoplication) is a procedure for treating GERD. Compared to laparoscopic surgery, TIF can result in quicker treatment duration, less pain, and a speedier recovery. A specific TIF device is used to make a path for an endoscope, a flexible, tube-like imaging instrument. The treatment allows the doctor to repair or replace the valve that acts as a natural barrier to reflux using preloaded tweezers and fasteners. Currently, clinical trials are being conducted to determine the efficacy of endoscopic therapy for GERD. An endoscopic sewing machine is used to insert stitches in the stomach, increasing the anti-reflux barrier. Thus, the market is expected to drive in the forecast period from the above statements.
Market Segmentation Analysis
Proton Pump Inhibitors segment is expected to hold the largest market share in gastroesophageal reflux disease therapeutics market
The proton pump inhibitors segment is expected to dominate in 2021. Proton pump inhibitors (PPIs) are the most widely used heartburn medication. They are the strongest available option for stopping acid production and are very convenient because they're so commonly used. Moreover, they are reported to effectively prevent the recurrence of reflux symptoms and esophageal erosions/ulcers. For instance, Esomeprazole (Nexium) is the prescription drug used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which the backward flow of acid from the stomach causes heartburn and possible injury to the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Therefore, it has increased the demand for drugs to treat gastroesophageal reflux disease. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Market Geographical Share
North America region holds the largest market share in the global gastroesophageal reflux disease therapeutics market
North America accounted for the highest revenue share in 2o21. Rising geriatric population, increasing prevalence of obesity cases, well-established infrastructure, increasing adoption of drugs for the gastroesophageal reflux disease and increasing clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, All U.S. states and territories have an obesity rate of at least 20%. Overall, adult obesity rates are higher for women. The percentage of obese children is rising, with 39 million overweight and obese children under age five in 2020. Moreover, the U.S. spends almost $150 billion per year on obesity-related medical costs, and early one in four young adults is too heavy to serve in the U.S. military.
Additionally, Ironwood Pharmaceuticals, Inc. conducted clinical trials in 2021 to evaluate the safety and efficacy of IW-3718 administered to patients with GERD. Therefore, it has increased the demand for gastroesophageal reflux drugs. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Recent Developments
April 2026: Ongoing clinical and research updates highlighted the role of newer therapies (including GLP-1-related studies and esophageal motility insights), indicating broader therapeutic exploration and comorbidity management in GERD treatment.
March 2026: A Phase IV post-marketing clinical study was initiated to evaluate the long-term safety and efficacy of vonoprazan 20 mg in GERD patients, reflecting continued expansion of real-world evidence for P-CAB therapies.
February 2026: Pharmaceutical companies, including Phathom Pharmaceuticals, signaled continued pipeline progress and commercialization strategies for GERD treatments, reinforcing momentum in novel acid-suppression therapies and lifecycle management.
January 2026: Braintree Laboratories (Sebela Pharmaceuticals) submitted a New Drug Application (NDA) to the U.S. FDA for tegoprazan, a next-generation potassium-competitive acid blocker (P-CAB) targeting multiple GERD indications, including erosive and non-erosive forms.
Market Major Companies
Major key players in the gastroesophageal reflux disease therapeutics market Merck Sharp & Dohme Pty Ltd., McNeil Consumer Pharmaceuticals Co., Amneal Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, Teva Pharmaceuticals USA, Inc., Takeda Pharmaceuticals America, Inc., Eisai R&D Management Co., Ltd, TWi Pharmaceuticals USA, Inc., Lannett and Saol Therapeutics Inc.
AstraZeneca Pharmaceuticals LP:
Overview:
AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which discovers, produces and commercializes a wide range of prescription drugs. It focuses on therapy areas such as respiratory, cardiovascular, renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. It operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
NEXIUM (esomeprazole magnesium): It is a proton pump inhibitor indicated for treating gastroesophageal reflux disease (GERD) and risk reduction of NSAID-associated gastric ulcers.
The global gastroesophageal reflux disease therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 160pages
